Charles River Laboratories International, Inc.
CRL
$166.91
-$2.73-1.61%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 984.17M | 1.00B | 1.01B | 1.03B | 1.01B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 984.17M | 1.00B | 1.01B | 1.03B | 1.01B |
| Cost of Revenue | 644.07M | 688.77M | 642.00M | 658.39M | 658.79M |
| Gross Profit | 340.10M | 313.78M | 367.77M | 367.73M | 352.77M |
| SG&A Expenses | 176.32M | 194.43M | 187.01M | 165.16M | 177.22M |
| Depreciation & Amortization | 29.76M | 41.22M | 32.40M | 32.27M | 32.58M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 850.15M | 924.43M | 861.41M | 855.81M | 868.58M |
| Operating Income | 134.01M | 78.12M | 148.35M | 170.31M | 142.98M |
| Income Before Tax | 35.98M | -216.79M | 91.24M | 119.65M | 99.01M |
| Income Tax Expenses | 10.10M | -3.04M | 20.95M | 25.39M | 24.53M |
| Earnings from Continuing Operations | 25.88M | -213.75M | 70.30M | 94.26M | 74.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -409.00K | -748.00K | -638.00K | -180.00K | -7.15M |
| Net Income | 25.47M | -214.50M | 69.66M | 94.08M | 67.33M |
| EBIT | 134.01M | 78.12M | 148.35M | 170.31M | 142.98M |
| EBITDA | 218.88M | 170.83M | 236.55M | 256.39M | 228.33M |
| EPS Basic | 0.50 | -4.22 | 1.34 | 1.75 | 1.31 |
| Normalized Basic EPS | 1.17 | 0.41 | 1.47 | 1.67 | 1.27 |
| EPS Diluted | 0.50 | -4.22 | 1.33 | 1.74 | 1.30 |
| Normalized Diluted EPS | 1.16 | 0.41 | 1.47 | 1.66 | 1.26 |
| Average Basic Shares Outstanding | 50.68M | 51.14M | 51.39M | 51.55M | 51.44M |
| Average Diluted Shares Outstanding | 50.85M | 51.14M | 51.58M | 51.85M | 51.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |